Article Figures & Data
Figures
- Fig 1.
Lateral STIR and T1-weighted MR images of various osteoporotic vertebral compression fractures with absent, partial, and full bone marrow edema (BME) before percutaneous vertebroplasty (PV) and lateral radiographic images after PV.
- Fig 2.
Osteoporotic vertebral compression fracture of L2 with absent bone marrow edema (BME) treated by percutaneous vertebroplasty (PV). Lateral STIR and T1-weighted MR images of the lumbar spine before and after PV. In the middle, lateral and anteroposterior radiographic images after PV.
- Fig 3.
Osteoporotic vertebral compression fractures of L1 and L3 with partial bone marrow edema (BME) treated by percutaneous vertebroplasty (PV). Lateral STIR and T1-weighted MR images of the lumbar spine before and after PV. In the middle are lateral and anteroposterior radiographic images after PV.
- Fig 4.
Osteoporotic vertebral compression fracture of L1 with full bone marrow edema (BME) treated by percutaneous vertebroplasty (PV). Lateral STIR and T1-weighted MR images of the lumbar spine before and after PV. In the middle, lateral and anteroposterior radiographic images after PV.
- Fig 5.
Visual analog score (VAS) for pain both preprocedure (0 months) and at follow-up periods after percutaneous vertebroplasty (PV) in patients with absent bone marrow edema (no BME) in treated vertebral compression fractures and patients with full BME in treated VCF.
- Fig 6.
Analgesic use both before percutaneous vertebroplasty (PV) (0 months) and at follow-up periods after PV in patients with absent bone marrow edema (no BME) in treated vertebral compression fractures (VCF) and patients with full BME in treated VCF. NSAID indicates nonsteroidal anti-inflammatory drug.
Tables
- Table 1:
Characteristics of patients with absent bone marrow edema (no BME) in treated osteoporotic vertebral compression fractures (VCF) (group I) and patients with full BME (full BME) in treated VCF (group II) prior to percutaneous vertebroplasty (PV)
Group I, No BME Group II, Full BME P value Total no. of study patients 14 31 Mean age, y (range) 71 (47–88) 75 (51–88) .5 Median 69 70 Women (%) 12 (86) 27 (87) .9 No. of VCF treated by PV 22 38 .01 Patients with multiple treated VCF (%) 7 (50) 7 (23) .1 Mean age treated VCF, (no) (range) 8.3 (3–36) 4.7 (2–24) .07 Median 5.5 3.0 Extent bone marrow edema in treated VCF Absent (0%) 22 Full (100%) 38 Shape of treated VCF Wedge (%) 17 (77) 28 (74) .7 Biconcave (%) 5 (23) 9 (24) Crush (%) 1 (2) Grade of treated VCF Mild (%) 14 (64) 8 (21) <.01 Moderate (%) 8 (36) 14 (37) Severe (%) 16 (42) Mean injected cement volume, mm3 (range) 3.5 (1.2–5.5) 2.7 (1.0–4.5) <.01 Median 4.0 2.5 Mean initial VAS (range) 8.6 (7–10) 8.6 (6–10) .9 Median 8.0 9.0 Initial analgesic use No (%) 14 0 .2 Paracetamol (%) 14 16 NSAID (%) 29 29 Opiate derivative (%) 43 55 Note:—VAS indicates visual analogue score; NSAID, nonsteroidal anti-inflammatory drug.
- Table 2:
Decrease in mean visual analogue score (VAS) for pain and analgesics used at 1 and 3 months after percutaneous vertebroplasty (PV) in patients with vertebral compression fractures (VCF) with absent bone marrow edema (no BME) prior to PV and patients with full BME (full BME) in treated VCF
Follow-up Period after PV 1 Month 3 Months Mean Decrease VAS Mean Decrease Analgesics Mean Decrease VAS Mean Decrease Analgesics No BME 5.1 43% 0.4 0% Full BME 5.8 84% 0.5 13% Regression coefficient .7 .9 .09 .07 99% Confidence interval −1–2.4 0.1–1.7 −0.7–0.9 −0.4–0.5 - Table 3:
Pain response at both follow-up intervals after percutaneous vertebroplasty (PV) in patients without bone marrow edema (BME) in treated vertebral compression fractures (VCF) prior to PV and patients with severe BME in treated VCF prior to PV
Follow-up Period after PV 1 Month 3 Months No BME Severe BME P Value No BME Severe BME P Value Pain unchanged at treated level(s) 4 (29%) 2 (6%) .04 4 (29%) 1 (3%) .01 Pain decrease at treated level(s) 10 (71%) 29 (94%) .04 10 (71%) 30 (97%) .01 Back pain decrease in general 9 (64%) 27 (87%) .08 9 (64%) 23 (74%) .4 Pain at untreated other level with no diagnostic substrate 1 (7%) 2 (6%) .9 1 (7%) 6 (19%) .3 Symptomatic new VCF 0 1 (3%) .5
